Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections
감염 후 SARS-CoV-2 변종에 대한 교차 중화 폭 및 수명
Article
[키워드] acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
Against
Antibody titer
Antibody titers
B.1.1.7
B.1.351
breadth
center
convalescent sera
coronavirus
coronavirus 2
coronavirus disease
Coronavirus disease 2019
COVID-19
cross-neutralizing
D614G
D614G mutation
decrease
epitope
Epitopes
infected with SARS-CoV-2
Infection
Longevity
maintain
neutralization
Neutralizing activity
Neutralizing antibodies
neutralizing antibody
Neutralizing antibody titer
neutralizing antibody titers
not significantly different
P.1
pandemic
Patient
patients
produced
Protective
public health
recognize
respiratory
responsible
SARS-CoV-2
SARS-CoV-2 variant
SARS-CoV-2 variants
selected
sera
several variant
several variants
Severe acute respiratory syndrome
severe acute respiratory syndrome Coronavirus
significantly
sustained
variant
variants
variants of concern
virus
Virus neutralization
viruses
VoC
VOCs
was performed
[DOI] 10.3389/fimmu.2022.773652 PMC 바로가기 [Article Type] Article
[DOI] 10.3389/fimmu.2022.773652 PMC 바로가기 [Article Type] Article